查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014469

子宮內膜異位症治療市場：依治療方法、給藥途徑、最終用戶和分銷管道分類－2026-2032年全球市場預測

Endometriosis Treatment Market by Treatment Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，子宮內膜異位症治療市場價值將達到 32.7 億美元，到 2026 年將成長至 35.1 億美元，到 2032 年將達到 54.8 億美元，複合年成長率為 7.65%。

主要市場統計數據
基準年 2025 32.7億美元
預計年份：2026年 35.1億美元
預測年份 2032 54.8億美元
複合年成長率 (%) 7.65%

全面概述了塑造現代子宮內膜異位症治療生態系統的不斷發展的臨床方法、患者路徑和相關人員的優先事項。

子宮內膜異位症是一種複雜的慢性婦科疾病，其臨床需求多樣，且需要長期治療。近年來，該領域在診斷方法、患者期望、醫療服務管道和治療方法創新方面都發生了顯著變化。這些變化要求臨床醫生、保險公司、製藥公司和醫療服務提供者重新評估現有的診療實踐，並適應以及時診斷、個體化管理和全面患者支持為核心的新環境。

重建子宮內膜異位症的診斷路徑、照護模式和治療方案：檢驗快速的臨床、技術和病患相關變化。

由於臨床實踐的進步、技術的普及、保險覆蓋範圍的變化以及患者社群活動的日益活躍等多種因素，子宮內膜異位症的治療格局正在改變。臨床上，人們越來越重視早期發現，並更明確地需要整合多面向介入措施，例如根據需要結合荷爾蒙療法、疼痛管理和微創手術。同時，診斷輔助工具和數位化分流工具正在縮短患者轉診至專科醫生的時間，從而重塑患者進入治療流程的地點和時間。

分析美國 2025 年的關稅措施及其對供應鏈、籌資策略和子宮內膜異位症患者治療的連鎖影響。

關稅調整等政策措施會對藥品和醫療設備的整個供應鏈產生連鎖反應。美國2025年宣布的關稅措施尤其受到參與子宮內膜異位症治療的利害關係人的關注。關稅帶來的成本壓力可能導致供應商選擇和採購慣例的改變，進而影響子宮內膜異位症治療中使用的活性成分、成品藥和手術耗材的採購。這些變化可能會增加依賴進口的供應鏈的管理複雜性，並促使企業採取區域籌資策略。

深入了解決定子宮內膜異位症臨床優先事項和服務提供的治療領域、資產回報率 (ROA)、醫療保健環境和通路。

有效的細分能夠識別臨床需求的差異點以及可以改善營運的領域。就治療類型而言，子宮內膜異位症的治療涵蓋輔助療法、荷爾蒙療法、疼痛管理和手術治療。荷爾蒙療法包括Aromatase抑制劑、促性腺激素釋放激素促效劑、促性腺激素釋放激素拮抗劑、口服避孕藥和黃體素等，每種藥物的療效、耐受性和監測需求各不相同。疼痛管理策略包括使用非類固醇消炎劑（NSAIDs）和鴉片類藥物。 NSAIDs通常以雙氯芬酸鈉、Ibuprofen和萘普生等藥物為代表，而鴉片類藥物通常包括可待因和氫可酮衍生物。這些藥物的選擇需要遵循不同的安全監測和處方規範。

對美洲、歐洲、中東和非洲以及亞太地區的臨床實務、報銷架構和病患就醫狀況進行區域分析，比較子宮內膜異位症的現況。

區域趨勢對子宮內膜異位症的診療方式和取得途徑有顯著影響，各大區域在診療模式、法規環境和支付方政策方面有顯著差異。美洲地區通常兼具公立和私立保險公司，擁有集中化的專科中心，微創手術技術的應用日益普及。同時，新藥療法的可近性取決於保險公司的政策和與區域供應商的關係。相較之下，歐洲、中東和非洲（EMEA）地區的國家醫療保健體系、監管時間表和報銷規則呈現出多樣化且錯綜複雜的局面，導致新治療方法的採用率各不相同，對不孕症預防方法的重視程度也存在差異。

為領導者提供具體建議，以加速子宮內膜異位症的診斷、最佳化治療途徑、加強供應鏈和改善患者照護。

實際可行且優先的措施將有助於各機構加速改善子宮內膜異位症的診療水平。首先，應增加對臨床醫生和基層醫療人員的培訓投入，以減少診斷延誤，並確保始終遵循指南建議的轉診途徑。早期發現能夠簡化診療流程，並拓展治療選擇。其次，應透過強調真實世界療效、生活品質指標和療效比較，使實證策略與保險公司的優先事項保持一致，從而支持關於保險覆蓋範圍和納入處方藥清單的討論。

對研究框架、資料收集和檢驗過程以及用於深入了解子宮內膜異位症治療的分析方法進行清晰的說明。

本研究採用結構化、多維度的方法，確保研究結果的穩健性和可靠性。關鍵的定性資料包括對臨床醫生、採購負責人和患者權益組織代表的詳細訪談，並輔以同行評審的臨床研究、監管指南和臨床實踐指南的文獻綜述。透過交叉比對這些訊息，檢驗了主題分析結果，並識別出臨床實踐和營運決策中的通用模式。

旨在為改善子宮內膜異位症的診斷、醫療保健服務和患者預後，對關鍵發現和意義進行全面總結，以便優先考慮相關人員。

總之，此綜合分析結合了臨床、營運和商業性觀點，明確了策略重點。診斷延遲、治療方案可用性差異以及供應鏈脆弱性被認為是影響患者體驗和系統表現的持續性挑戰。為應對這些挑戰，結合臨床醫生教育、實證實踐、彈性採購和以患者為中心的服務設計等協作策略，是實現持續改進的最有希望的途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 子宮內膜異位症治療市場（依治療方法分類）

  • 輔助療法
  • 荷爾蒙療法
    • Aromatase抑制劑
    • GnRH促效劑
    • GnRH拮抗劑
    • 口服避孕藥
    • 黃體素
  • 疼痛管理
    • NSAIDs
      • 雙氯芬酸鈉
      • Ibuprofen
      • 萘普生
    • 鴉片類藥物
      • 可待因
      • 氫可酮
  • 手術治療

第9章 子宮內膜異位症治療市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用

第10章 子宮內膜異位症治療市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章 子宮內膜異位症治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 子宮內膜異位症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 子宮內膜異位症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 子宮內膜異位症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國子宮內膜異位症治療市場

第16章 中國子宮內膜異位症治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Anika Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Beijing Biote Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Ferring International Center SA
  • Gedeon Richter Plc
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Merck & Co., Inc.
  • Myovant Sciences Ltd.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • ObsEva SA
  • Pfizer Inc.
  • Repros Therapeutics Inc.
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4348D129FA88

The Endometriosis Treatment Market was valued at USD 3.27 billion in 2025 and is projected to grow to USD 3.51 billion in 2026, with a CAGR of 7.65%, reaching USD 5.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.27 billion
Estimated Year [2026] USD 3.51 billion
Forecast Year [2032] USD 5.48 billion
CAGR (%) 7.65%

Comprehensive introduction to evolving clinical approaches, patient pathways, and stakeholder priorities shaping modern endometriosis treatment ecosystems

Endometriosis is a complex, chronic gynecologic condition that drives diverse clinical needs and long trajectories of care. Over recent years, the field has experienced substantive changes in diagnostic approaches, patient expectations, care delivery pathways, and therapeutic innovation. These shifts require clinicians, payers, manufacturers, and care providers to reassess established routines and adapt to an environment where timely diagnosis, individualized management, and holistic patient support are paramount.

The introduction situates readers at the intersection of clinical practice and health system dynamics. It synthesizes contemporary challenges such as diagnostic delays, variability in surgical and medical management, and the increasing prominence of patient-reported outcomes. It also highlights the drivers of change, including technology-enabled diagnostics, new pharmacologic mechanisms, and evolving reimbursement pressures. By framing the topic across clinical, operational, and commercial dimensions, the narrative sets expectations for strategic priorities, stakeholder trade-offs, and implementation barriers that will be explored in subsequent sections.

In sum, this introductory perspective aims to equip decision-makers with a concise orientation to the current landscape, clarifying why integrated strategies that bridge clinical evidence, supply continuity, and patient-centered services are essential to improving long-term outcomes and operational performance.

Examination of rapid clinical, technological, and patient shifts reshaping diagnostic pathways, care delivery models and therapeutic choices in endometriosis care

The landscape of endometriosis treatment is shifting under the combined influence of clinical advances, technology diffusion, payer recalibration, and more engaged patient communities. Clinically, there is a clearer emphasis on earlier recognition and on integrating multimodal interventions that combine hormonal management, pain control, and minimally invasive surgery when indicated. Concurrently, diagnostic adjuncts and digital triage tools are starting to reduce time to specialist referral, reshaping where and when patients enter care pathways.

On the commercial and operational side, manufacturers and providers are adapting to more differentiated therapeutic portfolios and variable reimbursement environments. Payers and health systems are prioritizing interventions that demonstrably reduce downstream resource utilization and improve quality of life, prompting deeper scrutiny of comparative effectiveness and real-world evidence. Patient advocacy and shared decision-making are also redefining value frameworks: patients increasingly weigh symptom control, fertility preservation, and quality-of-life impacts when evaluating therapy options.

Taken together, these transformative shifts compel stakeholders to reevaluate product development strategies, provider education, and access initiatives. Successful actors will align clinical evidence generation with pragmatic implementation plans that account for evolving diagnostic workflows, heterogeneous care settings, and rising expectations for patient-centered outcomes.

Analysis of US tariff measures in 2025 and their cascading effects on supply chains, procurement strategies, and patient access to endometriosis therapies

Policy levers such as tariff changes can ripple through pharmaceutical and device supply chains, and the announced United States tariff measures for 2025 warrant careful attention from stakeholders involved in endometriosis care. Tariff-driven cost pressures may alter supplier selection and procurement practices, with implications for sourcing of active pharmaceutical ingredients, finished medicines, and surgical consumables used in endometriosis management. These dynamics can raise the administrative complexity of import-dependent supply lines and incentivize regional sourcing strategies.

Operational teams must anticipate how increased import costs could influence inventory policy, contracting cadence, and strategic stockpiles. Procurement groups may respond by seeking diversified supplier networks, negotiating longer-term agreements, or shifting toward larger consolidated purchases to mitigate volatility. Providers and specialty clinics should evaluate formulary implications as product economics change; meanwhile, manufacturers may consider localized manufacturing or tolling arrangements to preserve competitive pricing and minimize distribution friction.

From a patient access perspective, tariff-induced disruptions can reshape availability patterns across distribution channels and care settings. Transitional mitigation measures, such as advance purchase agreements, consolidated logistics, and collaborative sourcing among provider networks, can attenuate short-term impacts. Ultimately, stakeholders that proactively assess supply chain exposures and adapt procurement strategies will be better positioned to sustain uninterrupted care and preserve therapeutic choice for patients.

Insights into treatment segments, ROA, care settings, and distribution pathways that inform clinical priorities and service delivery for endometriosis

Meaningful segmentation illuminates where clinical needs diverge and where operational levers can be applied. When viewed through treatment type, endometriosis management spans Complementary Therapies, Hormonal Therapies, Pain Management, and Surgical Treatment. Hormonal Therapies encompass classes such as Aromatase Inhibitors, GnRH Agonists, GnRH Antagonists, Oral Contraceptives, and Progestins, each carrying distinct efficacy profiles, tolerability considerations, and monitoring needs. Pain Management strategies include the use of NSAIDs and Opioids, and the NSAID category itself is commonly represented by agents such as Diclofenac, Ibuprofen, and Naproxen, while opioid options frequently involve codeine and morphine derivatives; these choices implicate different safety monitoring and prescribing frameworks.

Route of administration is another critical differentiator, with injectable, oral, and topical modalities shaping adherence dynamics, clinic visit frequency, and supply logistics. End user settings also matter materially: ambulatory surgical centers, hospitals, and specialty clinics each offer different procedural capabilities, perioperative protocols, and patient throughput considerations that affect treatment sequencing. Distribution channels complete the segmentation picture, as hospital pharmacy, online pharmacy, and retail pharmacy pathways influence inventory management, patient access timelines, and opportunities for therapeutic counseling.

By synthesizing these layers, stakeholders can identify intervention points for clinical education, formulary design, and targeted service models. Strategic decisions that reflect the interplay between therapeutic class, administration route, care setting, and distribution pathway will more effectively meet heterogeneous patient needs and streamline operational execution.

Regional analysis of clinical practice, reimbursement frameworks, and patient access that contrasts the Americas, EMEA, and Asia-Pacific landscapes in endometriosis

Regional dynamics exert a strong influence on how endometriosis care is delivered and accessed, with meaningful variation in practice patterns, regulatory environments, and payer policies across major geographies. The Americas tend to reflect a mix of private and public payer arrangements, with centralized centers of excellence and growing adoption of minimally invasive surgical techniques, while access to new pharmacologic options varies according to payer policy and regional supplier relationships. By contrast, Europe, the Middle East & Africa display a heterogeneous mosaic of national healthcare systems, regulatory timelines, and reimbursement rules, leading to varied adoption rates for novel therapies and differing emphases on fertility-preserving approaches.

Asia-Pacific markets present additional diversity: some jurisdictions prioritize rapid adoption of innovative diagnostics and telehealth-enabled care pathways, while others face access constraints driven by supply chain complexity and differing reimbursement priorities. Across regions, the balance between hospital-centric procedures and ambulatory care alternatives affects where patients receive surgery and follow-up, and distribution channel maturity-from hospital pharmacy networks to rapidly growing online pharmacy services-shapes patient access to both acute and maintenance therapies.

Understanding these regional contrasts enables more precise allocation of resources, localized evidence generation, and commercially realistic access strategies. Stakeholders should tailor clinical support, pricing strategies, and supply models to regional regulatory imperatives and patient access realities to optimize outcomes and sustainability.

Companies operating in the endometriosis ecosystem are pursuing a range of strategic plays that impact innovation velocity and market dynamics. Established therapeutics manufacturers continue to optimize existing portfolios while selectively advancing next-generation hormonal agents and novel mechanisms that target pain and lesion progression. At the same time, smaller biopharma and device innovators focus on niche indications, adjunctive therapies, and technology-enabled diagnostics designed to improve time to diagnosis and personalize treatment selection.

Across the competitive landscape, partnership models-such as licensing agreements, co-development collaborations, and distribution alliances-are increasingly important for accelerating access and sharing developmental risk. Strategic positioning also extends to capabilities in real-world evidence generation and patient engagement programs, which influence payer negotiations and clinician adoption. Firms that invest in demonstrable outcomes, streamlined manufacturing footprints, and resilient supply chains will reduce barriers to adoption and build stronger payer and provider relationships.

Ultimately, corporate strategic choices around R&D prioritization, commercial models, and ecosystem partnerships will determine who can scale innovations most effectively. Companies that integrate clinical evidence with pragmatic deployment strategies and robust patient support systems will emerge best positioned to deliver sustainable impact across the patient journey.

Actionable recommendations for leaders to expedite diagnosis, refine therapeutic pathways, strengthen supply resilience, and elevate patient care in endometriosis

Actionable, prioritized steps can help organizations accelerate meaningful improvements in endometriosis care. First, invest in clinician and primary care education to reduce diagnostic delays and ensure consistent use of guideline-based referral pathways; earlier identification streamlines care and expands therapeutic options. Second, align evidence-generation strategies with payer priorities by emphasizing real-world outcomes, quality-of-life metrics, and comparative effectiveness to support coverage discussions and formulary inclusion.

Third, strengthen supply chain resilience by diversifying suppliers, exploring regional manufacturing options, and implementing strategic inventory practices to mitigate tariff or logistics disruptions. Fourth, design patient-centered service models that integrate pharmacologic management, pain control strategies, fertility counseling, and psychosocial support to address the multifaceted needs of individuals living with the condition. Fifth, leverage digital tools to facilitate remote monitoring, adherence support, and triage, thereby reducing unnecessary visits and enhancing continuity of care.

When implemented cohesively, these recommendations create a reinforcing cycle: better diagnosis and tailored therapies improve outcomes, which in turn support payer value arguments and stabilize revenue streams necessary for continued innovation. Leaders should prioritize interventions that deliver measurable clinical benefit while remaining operationally feasible within existing care infrastructures.

Clear description of research framework, data collection and validation processes, and analytical methods applied to derive insights on endometriosis care

This research applied a structured, multi-source approach to ensure the robustness and credibility of findings. Primary qualitative inputs included in-depth interviews with clinicians, procurement specialists, and patient advocates, complemented by secondary literature reviews of peer-reviewed clinical studies, regulatory guidances, and practice guidelines. Triangulation across these inputs was used to validate thematic findings and identify consistent patterns across clinical practice and operational decision-making.

Analytical methods combined qualitative synthesis with scenario-based supply chain mapping and stakeholder impact analysis. Validation protocols included cross-checking interview insights with publicly available regulatory documents and procedural standards, and applying sensitivity checks to assumptions about care delivery pathways. Wherever possible, the research emphasized transparent linkage between evidence sources and derived conclusions, enabling users to trace how specific insights were developed.

The methodology prioritized reproducibility, clarity of assumptions, and contextual interpretation rather than predictive quantification. Clear documentation of data sources, interview frameworks, and analytic logic supports downstream application by clinicians, commercial teams, and procurement professionals seeking to adapt the insights to their own operational contexts.

Concluding synthesis of key findings and implications setting priorities for stakeholders to improve diagnosis, care delivery, and patient outcomes in endometriosis

The concluding synthesis brings together clinical, operational, and commercial perspectives to clarify strategic priorities. Delays in diagnosis, heterogeneous adoption of therapeutic options, and supply chain vulnerabilities emerge as persistent themes that shape patient experience and system performance. In response, coordinated strategies that combine clinician education, evidence generation, resilient procurement, and patient-focused service design provide the most promising avenue for durable improvement.

Stakeholders should prioritize interventions that deliver tangible clinical benefit while also addressing logistical constraints that influence access and adherence. Examples include bolstering pathways for early specialist referral, aligning therapeutic value propositions with payer evidence needs, and investing in supply chain redundancies that reduce the risk of therapeutic interruptions. Importantly, integrating patient voice into research and service design amplifies relevance and can accelerate uptake through demonstrable improvements in quality of life.

In summary, the path forward requires multidisciplinary collaboration and pragmatic implementation. By aligning scientific innovation with operational realism and patient priorities, the sector can advance meaningful improvements in care delivery and outcomes for people affected by endometriosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometriosis Treatment Market, by Treatment Type

  • 8.1. Complementary Therapies
  • 8.2. Hormonal Therapies
    • 8.2.1. Aromatase Inhibitors
    • 8.2.2. Gnrh Agonists
    • 8.2.3. Gnrh Antagonists
    • 8.2.4. Oral Contraceptives
    • 8.2.5. Progestins
  • 8.3. Pain Management
    • 8.3.1. Nsaids
      • 8.3.1.1. Diclofenac
      • 8.3.1.2. Ibuprofen
      • 8.3.1.3. Naproxen
    • 8.3.2. Opioids
      • 8.3.2.1. Codeine
      • 8.3.2.2. Morphine
  • 8.4. Surgical Treatment

9. Endometriosis Treatment Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Endometriosis Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Endometriosis Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Endometriosis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endometriosis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endometriosis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endometriosis Treatment Market

16. China Endometriosis Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amneal Pharmaceuticals Inc.
  • 17.7. Anika Therapeutics, Inc.
  • 17.8. Astellas Pharma Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Bayer AG
  • 17.11. Beijing Biote Pharmaceutical Co., Ltd.
  • 17.12. Eli Lilly and Company
  • 17.13. Ferring International Center S.A.
  • 17.14. Gedeon Richter Plc
  • 17.15. Janssen Pharmaceuticals
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. Kissei Pharmaceutical Co., Ltd.
  • 17.18. Livzon Pharmaceutical Group Inc.
  • 17.19. Merck & Co., Inc.
  • 17.20. Myovant Sciences Ltd.
  • 17.21. Neurocrine Biosciences, Inc.
  • 17.22. Novartis AG
  • 17.23. ObsEva SA
  • 17.24. Pfizer Inc.
  • 17.25. Repros Therapeutics Inc.
  • 17.26. Sanofi S.A.
  • 17.27. Shionogi & Co., Ltd.
  • 17.28. Takeda Pharmaceutical Company Limited
  • 17.29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)